Hemostasis in the 21st century

Netherlands Journal of Medicine

Volumn 55, Issue 6, 1999, Pages 280-286

  Levi, Marcel ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 9; PROTEIN C; PROTHROMBIN; RECOMBINANT BLOOD CLOTTING FACTOR 8; THROMBIN; THROMBOPLASTIN;

ARTICLE; BLOOD CLOTTING; HEMOSTASIS; HUMAN; SCIENCE; THROMBOCYTE; THROMBOSIS;

ANTICOAGULANTS; BLOOD COAGULATION DISORDERS; HEMOSTASIS; HUMANS; THROMBOSIS;

EID: 0032720128     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0300-2977(99)00099-6     Document Type: Article

References (35)

1. Davie E.W. Biochemical and molecular aspects of the coagulation cascade. Thromb Haemost. 74:1995;1-6.
2. Rapaport S.I., Rao L.V. The tissue factor pathway: how it has become a 'prima ballerina'. Thromb Haemost. 74:1995;7-17.
3. Verstraete M. The fibrinolytic system: from Petri dishes to genetic engineering. Thromb Haemost. 74:1995;25-35.
4. ten Cate H., Bauer K.A., Levi M., et al. The activation of factor X and prothrombin by recombinant factor VIIa in vivo is mediated by tissue factor. J Clin Invest. 92:1993;1207-1212.
5. Schafer A.I. Hypercoagulable states: molecular genetics to clinical practice. Lancet. 344:1994;1739-1742.
6. Bouma B.N., von dem Borne P.A., Meijers J.C. Factor XI and protection of the fibrin clot against lysis - a role for the intrinsic pathway of coagulation in fibrinolysis. Thromb Haemost. 80:1998;24-27.
7. Solovey A., Lin Y., Browne P., Choong S., Wayner E., Hebbel R.P. Circulating activated endothelial cells in sickle cell anemia. New Engl J Med. 337:1997;1584-1590.
8. Poort S.R., Rosendaal F.R., Reitsma P.H., Bertina R.M. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 88:1996;3698-3703.
9. Kuter D.J., Cebon J., Harker L.A., Petz L.D., McCullough J. Platelet growth factors: potential impact on transfusion medicine. Transfusion. 39:1999;321-332.
10. Stouffer G.A., Runge M.S. The role of secondary growth factor production in thrombin-induced proliferation of vascular smooth muscle cells. Semin Thromb Hemost. 24:1998;145-150.
11. Carmeliet P., Mackman N., Moons L., et al. Role of tissue factor in embryonic blood vessel development. Nature. 383:1996;73-75.
12. Carmeliet P., Moons L., Collen D. Mouse models of angiogenesis, arterial stenosis, atherosclerosis and hemostasis. Cardiovasc Res. 39:1998;8-33.
13. Pixley R.A., De L.C., Page J.D., et al. The contact system contributes to hypotension but not disseminated intravascular coagulation in lethal bacteremia. In vivo use of a monoclonal anti-factor XII antibody to block contact activation in baboons. J Clin Invest. 91:1993;61-68.
14. Levi M., Hack C.E., de Boer J.P., Brandjes D.P.M., Büller H.R., ten Cate J.W. Reduction of contact activation related fibrinolytic activity in factor XII deficient patients: Further evidence for the role of the fibrinolytic system in vivo. J Clin Invest. 88:1991;1155-1160.
15. Kasper C.K., Mannucci P.M., Bulyzhenkov V., et al. Haemophilia in the 1990s: report of a joint meeting of the World Health Organization and World Federation of Hemophilia. Vox Sang. 61:1991;221-224.
16. Gitschier J., Wood W.I., Goralka T.M., et al. Characterization of the human factor VIII gene. Nature. 312:1984;326-330.
17. Wood W.I., Capon D.J., Simonsen C.C., et al. Expression of active human factor VIII from recombinant DNA clones. Nature. 312:1984;330-337.
18. Choo K.H., Gould K.G., Rees D.J., Brownlee G.G. Molecular cloning of the gene for human anti-haemophilic factor IX. Nature. 299:1982;178-180.
19. Guidelines on therapeutic products to treat haemophilia and other hereditary coagulation disorders. Haemophilia. 3:1997;63-77.
20. Lee C. Recombinant clotting factors in the treatment of hemophilia. Thromb Haemost. 82:1999;516-524.
21. Fields P.A., Pasi K.J. Gene therapy for haemophilia: how far have we come? Haemophilia. 4:1998;699-703.
22. Connelly S., Kaleko M. Gene therapy for hemophilia A. Thromb Haemost. 78:1997;31-36.
23. Herzog R.W., High K.A. Adeno-associated virus-mediated gene transfer of factor IX for treatment of hemophilia B by gene therapy. Thromb Haemost. 82:1999;540-546.
24. Greengard J.S., Jolly D.J. Animal testing of retroviral-mediated gene therapy for factor VIII deficiency. Thromb Haemost. 82:1999;555-561.
25. Bertina R.M. Molecular risk factors for thrombosis. Thromb Haemost. 82:1999;601-609.
26. Bertina R.M., Koeleman B.P., Koster T., et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 369:1994;64-67.
27. den Heijer M., Koster T., Blom H.J., et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. New Engl J Med. 334:1996;759-762.
28. Koster T., Blann A.D., Briet E., Vandenbroucke J.P., Rosendaal F.R. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet. 345:1995;152-155.
29. Rosendaal F.R. Risk factors for venous thrombotic disease. Thromb Haemost. 82:1999;619.
30. Levi M., ten Cate H. Current concepts. Disseminated intravascular coagulation. New Engl J Med. 341:1999;586-592.
31. Weitz J.I., Hudoba M., Massel D., Maraganore J., Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest. 86:1990;385-391.
32. Biemond B.J., Friederich P.W., Levi M., Vlasuk G.P., Buller H.R., ten Cate J.W. Comparison of sustained antithrombotic effects of inhibitors of thrombin and factor Xa in experimental thrombosis. Circulation. 93:1996;153-160.
33. Cannon C.P., Braunwald E. Hirudin: initial results in acute myocardial infarction, unstable angina and angioplasty. J Am Coll Cardiol. 25:1995;30S-37S.
34. Levi M., Peters R.J., Buller H.R. Weight watching in cardiology: low molecular weight heparin for acute coronary syndromes. Cardiovasc Res. 37:1998;564-566.
35. Kuivenhoven J.A., Jukema J.W., Zwinderman A.H., et al. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. New Engl J Med. 338:1998;86-93.